Information Provided By: 
Fly News Breaks for November 8, 2019
ATRA
Nov 8, 2019 | 08:08 EDT
JPMorgan analyst Anupam Rama downgraded Atara Biotherapeutics to Neutral from Overweight with a price target of $22, down from $43. The long-term fundamentals of the company are in place, but the shares are likely to be range bound in near- to intermediate-term "given a lack of game changing catalysts," Rama tells investors in a research note.
News For ATRA From the Last 2 Days
There are no results for your query ATRA
